Chemosaturation of the Liver – an Update

Sebastian Ebel; Manuel Florian Struck; Florian van Boemmel; Anne Bettina Beeskow; Holger Gößmann; Timm Denecke

doi:10.1055/a-1858-3418

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, Inhaltsverzeichnis

Rofo 2023; 195(01): 30-37
DOI: 10.1055/a-1858-3418

Interventional Radiology

Chemosaturation of the Liver – an Update

Artikel in mehreren Sprachen: English | deutsch

Sebastian Ebel

¹Klinik und Poliklinik für diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany

,

Manuel Florian Struck

²Klinik und Poliklinik für Anästhesiologie und Intensivtherapie, Leipzig University, Leipzig, Germany

,

Florian van Boemmel

³Klinik für Innere Medizin II, Sektion für Hepatologie, Leipzig University, Leipzig, Germany

,

Anne Bettina Beeskow

¹Klinik und Poliklinik für diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany

,

Holger Gößmann

¹Klinik und Poliklinik für diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany

,

Timm Denecke

¹Klinik und Poliklinik für diagnostische und interventionelle Radiologie, Leipzig University, Leipzig, Germany

› Institutsangaben

Abstract

Background Percutaneous hepatic perfusion (CS-PHP) is a treatment option for primary and secondary liver neoplasms and subject of intensive research. This present article provides an overview of CS-PHP regarding patient safety, feasibility and effectiveness based on recent studies.

Method We performed a PubMed search including the search terms chemosaturation, hepatic chemosaturation, percutaneous perfusion and melphalan.

Results and conclusion CS-PHP is a promising procedure for the treatment of uveal melanoma and cholangiocellular carcinoma. There are insufficient data regarding the effectiveness of CS-PHP with respect to other tumor entities. Since CS-PHP can be accompanied by multiple transient side effects and complications, close interdisciplinary cooperation is necessary.

Key Points:

Chemosaturation of the liver is a safe procedure.
CS-PHP is a potent therapy for hepatic metastatic ocular melanoma and cholangiocellular carcinoma.
The procedure requires close interdisciplinary coordination.
CS-PHP is a repeatable and thus long-term therapeutic option for some patients.

Citation Format

Ebel S, Struck MF, van Boemmel F et al. Chemosaturation of the Liver – an Update. Fortschr Röntgenstr 2023; 195: 30 – 37

Key words

abdomen - hematologic - angiography - interventional procedures

Volltext

Referenzen

References
1 Inc D Hepatic Delivery System Instructions for Use.
2 Meijer TS, Burgmans MC, Fiocco M. et al. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial. Cardiovasc Intervent Radiol 2019; 42: 841-852
3 Dewald CLA, Meine TC, Winther HMB. et al. Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) with Melphalan: Evaluation of 2D-Perfusion Angiography (2D-PA) for Leakage Detection of the Venous Double-Balloon Catheter. Cardiovasc Intervent Radiol 2019; 42: 1441-1448
4 Dewald CLA, Becker LS, Maschke SK. et al. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. Clin Exp Metastasis 2020; 37: 683-692
5 Struck MF, Kliem P, Ebel S. et al. Percutaneous hepatic melphalan perfusion: Single center experience of procedural characteristics, hemodynamic response, complications, and postoperative recovery. PLoS One 2021; 16
6 de Leede EM, Burgmans MC, Meijer TS. et al. Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan. Cardiovasc Intervent Radiol 2017; 40: 1196-1205
7 Forster MR, Rashid OM, Perez MC. et al. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: A single institution experience. J Surg Oncol 2014; 109: 434-439
8 Dewald CLA, Hinrichs JB, Becker LS. et al. Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma. RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgeb Verfahren 2021; 193: 928-936
9 Karydis I, Gangi A, Wheater MJ. et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. J Surg Oncol 2018; 117: 1170-1178
10 Marquardt S, Kirstein MM, Brüning R. et al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol 2019; 29: 1882-1892
11 Vogl TJ, Koch SA, Lotz G. et al. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. Cardiovasc Intervent Radiol 2017; 40: 864-872
12 Brüning R, Tiede M, Schneider M. et al. Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan – Long-Term Overall Survival Negatively Correlates with Tumor Burden. Radiol Res Pract 2020; 2020: 1-7
13 Schönfeld L, Hinrichs JB, Marquardt S. et al. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. J Cancer Res Clin Oncol 2020; 146: 3003-3012
14 Vogl TJ, Zangos S, Scholtz JE. et al. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Rofo 2014; 186: 937-944
15 Artzner C, Mossakowski O, Hefferman G. et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: A single center experience. Cancer Imaging 2019; 19: 1-8
16 Hughes MS, Zager J, Faries M. et al. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. Ann Surg Oncol 2016; 23: 1309-1319
17 Pingpank JF, Libutti SK, Chang R. et al. Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic Venous Hemofiltration Using Percutaneously Placed Catheters in Patients With Unresectable Hepatic Malignancies. J Clin Oncol 2008; 23: 3465-3474
18 Kirstein MM, Marquardt S, Jedicke N. et al. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors. J Cancer Res Clin Oncol 2017; 143: 2113-2121
19 Carr MJ, Sun J, Cohen JB. et al. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases. Cancer Control 2020; 27: 1-9
20 Ferrucci PF, Cocorocchio E, Bonomo G. et al. A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System. Cells 2021; 10
21 Onkologie L. S3-Leitlinie Früherkennung, Therapie und Nachsorge des Melanomes. 2020: 1-400
22 Feldman ED, Pingpank JF, Alexander HR. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004; 11: 290-297
23 Jovanovic P, Mihajlovic M, Djordjevic-Jocic J. et al. Ocular melanoma: An overview of the current status. Int J Clin Exp Pathol 2013; 6: 1230-1244
24 Gragoudas ES, Egan KM, Seddon JM. et al. Survival of Patents with Metastases from Uveal Melanoma. Ophthalmology 1991; 98: 383-390
25 Carvajal RD, Schwartz GK, Tezel T. et al. Metastatic disease from uveal melanoma: Treatment options and future prospects. Br J Ophthalmol 2017; 101: 38-44
26 Hawkins BS. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124: 1684-1693
27 Triozzi PL, Singh AD. Adjuvant Therapy of Uveal Melanoma: Current Status. Ocul Oncol Pathol 2015; 1: 54-62
28 Khoja L, Atenafu EG, Joshua AM. Meta-analysis of phase II trials in metastatic uveal melanoma (MUM) to determine progression-free (PFS) and overall survival (OS) benchmarks for future phase II trials: An irci-ocular melanoma initiative. J Clin Oncol 2016; 34: 9567
29 Xing M, Prajapati HJ, Dhanasekaran R. et al. Selective internal yttrium-90 radioembolization therapy (90Y-SIRT) versus best supportive care in patients with unresectable metastatic melanoma to the liver refractory to systemic therapy. Am J Clin Oncol 2017; 40: 27-34
30 Memon K, Kuzel TM, Vouche M. et al. Hepatic yttrium-90 radioembolization for metastatic melanoma: A single-center experience. Melanoma Res 2014; 24: 244-251
31 Gupta S, Bedikian AY, Ahrar J. et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: Response, survival, and prognostic factors. Am J Clin Oncol Cancer Clin Trials 2010; 33: 474-480
32 Ahrar J, Gupta S, Ensor J. et al. Response, survival, and prognostic factors after hepatic arterial chemoembolization in patients with liver metastases from cutaneous melanoma. Cancer Invest 2011; 29: 49-55
33 Gonsalves CF, Eschelman DJ, Adamo RD. et al. A prospective Phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology 2019; 293: 223-231
34 Veelken R, Maiwald B, Strocka S. et al Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol In Press 2021
35 Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int 2019; 39: 19-31
36 Benson AB, D’Angelica MI, Abbott DE. et al. Hepatobiliary cancers, Version 2.2021. JNCCN J Natl Compr Cancer Netw 2021; 19: 541-565
37 Rizvi S, Khan SA, Hallemeier CL. et al. Cholangiocarcinoma – evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 2018; 15: 95-111
38 Weber SM, Jarnagin WR, Klimstra D. et al. Intrahepatic Cholangiocarcinoma: resectability, recurrence pattern, and outcomes1 1No competing interests declared. J Am Coll Surg 2001; 193: 384-391
39 Jarnagin WR, Fong Y, DeMatteo RP. et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234: 507-519
40 Bridgewater J, Galle PR, Khan SA. et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60: 1268-1289
41 Onkologie L. Konsultationsfassung Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome Wesentliche Neuerungen in der Leitlinie zur Diagnostik und Therapie des hepatozellulären Karzinoms. 2021: 1-205
42 Akateh C, Ejaz AM, Pawlik TM. et al. Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. World J Hepatol 2020; 12: 693-708
43 Pingpank JF, Hughes MS, Alexander HR. et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol 2010; 28: LBA8512-LBA8512
44 Estler A, Artzner C, Nikolaou K. et al. Vorhersage des Tumoransprechens und Gesamtüberleben nach Chemosaturation bei hepatisch metastasiertem Aderhautmelanom. RöFo – Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgeb Verfahren 2021; 1: 10